High Risk/Recurrent/Advanced Prostate Cancer Virtual Group recording – 12/16/19
Topics discussed:
SHOW MORE
Topics discussed:
SHOW MORE
Topics discussed:
Is it OK for PSA to stabilize in the 20’s?; debulking the Primary tumor and iterating metastatic cells; repeating bicalutamide use; anti-fatigue drugs; generic abiraterone; shingles vaccines; HERO trial for relugolix; switching LHRH drugs; monotherapy anti-androgen treatment; using Technitium99 scan for darolutamide; can your MSI change over time?; pembrolizumab for PCa; your doctor’s attitude to you and your treatment; separating designated resources in your final wishes.
To view links referenced in this recording, please visit our Prostate Cancer Forum
Through my attendance at HealtheVoices 2019, I had the good fortune to meet Andrew Schorr, the founder of Patient Power. In their own words…… Patient Power® is devoted to supporting cancer patients, care partners and other loved ones through education and advocacy – to get the right treatment at the right time working with the right healthcare team.
A couple of months later I was approached to do an interview with their Prostate Cancer Community Manager, Andrea Hutton that I just learned was published on their PCa page in October. You can watch for yourself by clicking on this link ; hopefully for our veterans, there won’t be too much new. And from my standpoint, it’s a great visual lesson in how to improve my interviewing technique!!
Topics discussed:
Remembering Thibeaux Lincecum; SSDI approval won; new NHI PSMA initiatives – scan & curative; Paget’s Disease confused with PCa; bone biopsy protocol; biopsy slide preparation; denosumab – Xgeva v Prolia; PCRI recordings; recovering from RRP; our own mortality; does testosterone recovery impact PSA readings; glucose and PCa
Topics discussed:
Prof Bill Burhans’ memorial; how does enzalutamide/Xtandi work; debulking the primary tumor; glucose and glucosamine; does your age influence treatment delivered?; PBRT vs IMRT; milk based proteins, T.Colin Campbell and more; testosterone based therapies; End-of-Life planning